Standout Papers
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma (2017)
- American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects (2007)
- Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone (2011)
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up (2019)
Immediate Impact
5 by Nobel laureates 10 from Science/Nature 92 standout
Citing Papers
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
2022 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Works of David J. Vaughn being referenced
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
2019 Standout
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| David J. Vaughn | 5161 | 4583 | 2295 | 258 | 10.5k | |
| Jourik A. Gietema | 2326 | 3418 | 2001 | 251 | 9.8k | |
| Andrew M. Lowy | 4185 | 7327 | 2562 | 245 | 12.2k | |
| Luigi Dogliotti | 4905 | 4887 | 2514 | 197 | 11.0k | |
| Fernando Augusto Soares | 1914 | 3136 | 1884 | 395 | 9.5k | |
| Norio Nonomura | 2235 | 2319 | 3442 | 588 | 11.0k | |
| David I. Quinn | 4397 | 5656 | 4686 | 404 | 13.7k | |
| Bhuvanesh Singh | 3092 | 5593 | 4566 | 168 | 13.2k | |
| Curtis A. Pettaway | 3421 | 2847 | 3216 | 258 | 9.8k | |
| Georg Bartsch | 3721 | 1144 | 4223 | 336 | 10.4k | |
| Roy M. Bremnes | 2435 | 6199 | 4177 | 229 | 12.7k |
All Works
Login with ORCID to disown or claim papers
Loading papers...